DiagnoCure announces completion of investment of US$5 million by Gen-Probe Incorporated

    Ticker Symbol: CUR

    QUEBEC CITY, May 8 /CNW Telbec/ - DiagnoCure Inc. (TSX: CUR) announced
today that following the previously announced signature of the amendment to
its 2003 license agreement, with Gen-Probe Incorporated (NASDAQ:  GPRO), and
pursuant to the terms of this amendment, Gen-Probe has completed, on May 7,
2009, its subscription of 4.9 millions shares of newly issued DiagnoCure
convertible preferred shares for US$5.0 million, representing a premium of
19.8% over the average market price of the common shares of DiagnoCure during
the 20 trading days prior to April 28, 2009. These convertible preferred
shares are non-voting, and may be exchanged for common share on a one-for-one
basis. DiagnoCure has the option to redeem the preferred shares or to require
their conversion into common shares in certain circumstances. As part of its
investment in DiagnoCure, Gen-Probe will receive a liquidation preference in
certain cases and a security interest in some intellectual property.

    About DiagnoCure

    DiagnoCure (TSX: CUR) is a life sciences company commercializing
high-value cancer diagnostic tests and delivering laboratory services that
increase clinician and patient confidence in making critical treatment
decisions. DiagnoCure Oncology Laboratories, a subsidiary of DiagnoCure Inc.,
launched in 2008 the Previstage(TM) GCC Colorectal Cancer Staging Test, the
first GCC-based molecular test for the management of colorectal cancer. A
major study published in the February 18, 2009, edition of the JAMA ("Journal
of the American Medical Association") demonstrated that GCC, to which
DiagnoCure secured exclusive worldwide diagnostic rights, is the strongest
independent predictor of colorectal cancer recurrence. The Company also has a
strategic alliance with Gen-Probe (NASDAQ:   GPRO) for the development and
commercialization of a second-generation prostate cancer test using PCA3,
DiagnoCure's proprietary molecular marker. This test is also available through
laboratories in the U.S. using PCA3 analyte specific reagents (ASR) from
Gen-Probe, in Europe as the CE-marked PROGENSA(TM) PCA3 in vitro assay, and in
Canada. In addition to its own research, the Company intends to acquire or
in-license additional promising cancer biomarkers from both academic and
commercial institutions. For more information, visit www.diagnocure.com.

    Forward-looking statements

    This release contains forward-looking statements that involve known and
unknown risks, uncertainties and assumptions that may cause actual results to
differ materially from those expected. By their very nature, forward-looking
statements are based on expectations and hypotheses and also involve risks and
uncertainties, known and unknown, many of which are beyond DiagnoCure's
control. As a result, investors are cautioned not to place undue reliance on
these forward-looking statements. The forward-looking statements regarding the
outcome of research and development projects, clinical studies and future
revenues are based on management expectations. In addition, the reader is
referred to the applicable general risks and uncertainties described in
DiagnoCure's most recent Annual Information Form under the heading "Risk
Factors". DiagnoCure undertakes no obligation to publicly update or revise any
forward-looking statements contained herein unless required by the applicable
securities laws and regulations.

For further information:

For further information: Investors: J. F. Bureau, CFA, Sr. Vice
President and CFO, DiagnoCure Inc., (418) 527-6100,
communications@diagnocure.com; Media: Paule De Blois, Vice President,
Corporate Affairs, DiagnoCure Inc.,(418) 527-6100, p.deblois@diagnocure.com

Organization Profile

DiagnoCure Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890